Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting

These presentations will include clinical data, including recent analyses, from the core phase of the Company’s Phase IIb trial with MIN-101 as monotherapy for unmet needs in patients suffering from schizophrenia, particularly negative symptoms.


So they’ll be testing it as monotherapy.


Hope this drug make it to the market soon…!!!:pray:

Actually, they HAVE tested it as monotherapy. Sorry.


Positive symptoms were observed to remain stable,

I have no idea what that means.

Actually it probably follows on from this:

To participate in the trial, patients were required to have stable positive and negative symptoms for three months prior to entry.

1 Like

Good news thanks!

1 Like

How long does phase 3 usually take?

Wonder which negative symptoms it would even help. Hoping they discover treatments for anhedonia researching for MDD; that seems plausible.